Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 2,978 Shares

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 2,978 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.36, for a total value of $188,686.08. Following the completion of the sale, the chief executive officer now directly owns 392,589 shares in the company, valued at approximately $24,874,439.04. The trade was a 0.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Down 0.7 %

Shares of INSM traded down $0.47 during midday trading on Friday, reaching $65.25. 3,087,759 shares of the company were exchanged, compared to its average volume of 1,881,810. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The stock has a 50-day moving average price of $71.29 and a 200-day moving average price of $72.44. The company has a market cap of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same period in the prior year, the company earned ($1.10) earnings per share. The business’s revenue was up 18.1% compared to the same quarter last year. Research analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current year.

Hedge Funds Weigh In On Insmed

A number of hedge funds have recently bought and sold shares of INSM. CIBC Asset Management Inc grew its position in shares of Insmed by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 149 shares in the last quarter. Commerce Bank lifted its stake in Insmed by 2.4% during the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 163 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the period. Atomi Financial Group Inc. increased its stake in Insmed by 1.4% during the third quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock valued at $1,697,000 after purchasing an additional 314 shares during the last quarter. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Insmed during the third quarter worth $30,000.

Wall Street Analyst Weigh In

INSM has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, Bank of America lifted their price target on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.